- Home
- IVVD
IVVD
Invivyd Inc.
as 09-12-2025 4:00pm EST
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 63.4M | IPO Year: | 2021 |
| Target Price: | $3.64 | AVG Volume (30 days): | 15.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $2.74 | Next Earning Date: | 11-13-2025 |
| Revenue: | $46,210,000 | Revenue Growth: | 1941.08% |
| Revenue Growth (this year): | 385.94% | Revenue Growth (next year): | 62.62% |
Stock Insider Trading Activity of Invivyd Inc. (IVVD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Green Julie | IVVD | Chief Human Resources Officer | Aug 19 '25 | Sell | $0.57 | 29,643 | $16,795.72 | 49,344 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Aug 19 '25 | Sell | $0.57 | 49,402 | $27,991.17 | 84,446 | |
| Duke William E. | IVVD | Chief Financial Officer | Aug 19 '25 | Sell | $0.57 | 29,643 | $16,795.72 | 49,344 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Aug 19 '25 | Sell | $0.57 | 29,643 | $16,795.72 | 59,344 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Aug 19 '25 | Sell | $0.57 | 27,420 | $15,536.17 | 53,068 | |
| Green Julie | IVVD | Chief Human Resources Officer | Aug 18 '25 | Sell | $0.65 | 20,013 | $13,012.45 | 49,344 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Aug 18 '25 | Sell | $0.65 | 33,352 | $21,685.47 | 84,446 | |
| Duke William E. | IVVD | Chief Financial Officer | Aug 18 '25 | Sell | $0.65 | 20,013 | $13,012.45 | 49,344 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Aug 18 '25 | Sell | $0.65 | 20,013 | $13,012.45 | 59,344 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Aug 18 '25 | Sell | $0.65 | 18,512 | $12,036.50 | 53,068 |
Latest Invivyd Inc. News
IVVD Breaking Stock News: Dive into IVVD Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Could Invivyd's (IVVD) Expanding Antibody Pipeline Redefine Its Long-Term Therapeutic Strategy?
MT Newswires
24 days ago
Invivyd Closes $57.5 Million Public Offering
GlobeNewswire
24 days ago
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
MT Newswires
25 days ago
Update: Invivyd Shares Fall After Company Prices $50 Million Offering of Stock, Warrants
MT Newswires
25 days ago
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Jackson Hole Economic Symposium
MT Newswires
25 days ago
Invivyd Prices $50 Million Offering of Stock, Warrants
GlobeNewswire
25 days ago
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
MT Newswires
a month ago
Invivyd Announces Public Stock Offering
Compare IVVD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IVVD Invivyd Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.